Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adabelimab plus platinum-etoposide neoadjuvant/conversion therapy for stage IIB-III small cell lung cancer
ChiCTR2500098854Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Pathological complete response. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500098854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098854.